De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Immunotech Biopharm Balans Gezondheid
Financiële gezondheid criteriumcontroles 1/6
Immunotech Biopharm has a total shareholder equity of CN¥78.3M and total debt of CN¥285.8M, which brings its debt-to-equity ratio to 364.8%. Its total assets and total liabilities are CN¥719.7M and CN¥641.4M respectively.
Belangrijke informatie
364.8%
Verhouding schuld/eigen vermogen
CN¥285.79m
Schuld
| Rente dekkingsratio | n/a |
| Contant | CN¥145.31m |
| Aandelen | CN¥78.33m |
| Totaal verplichtingen | CN¥641.39m |
| Totaal activa | CN¥719.72m |
Recente financiële gezondheidsupdates
Analyse van de financiële positie
Kortlopende schulden: 6978's short term assets (CN¥180.8M) do not cover its short term liabilities (CN¥478.2M).
Langlopende schulden: 6978's short term assets (CN¥180.8M) exceed its long term liabilities (CN¥163.2M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 6978's net debt to equity ratio (179.3%) is considered high.
Schuld verminderen: 6978's debt to equity ratio has increased from 0% to 364.8% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 6978 has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: 6978 has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.6% each year.